Kimberly-Clark agreed to buy Kenvue in a cash-and-stock transaction that values the Tylenol maker at an enterprise value of about $48.7 billion, including debt. Under the terms of the deal, Kenvue shareholders will receive $21.01 a share, based on Kenvue’s closing price of $14.37 on Friday, the companies said. At closing, Kimberly-Clark shareholders will own roughly 54% of the combined company, with current Kenvue shareholders owning the remaining 46%.
Continue Reading
View Comments
Kimberly-Clark to Buy Tylenol Maker Kenvue. Why Kimberly-Clark Stock Is Tanking.
Published 1 week ago
Nov 3, 2025 at 2:35 PM
Positive
Auto